Vivo study using tumor mice model showed that P-Cis plus PD1/PD-L1 inhibitors had synergistic and therapeutic advantages compared with traditional cisplatin plus PD1/PD-L1 inhibitors (75). The gene discussed is CD274; the disease is neoplasm.